Provectus net loss narrows 46.6% to $988,716 in Q2 FY26

PUBT · 2d ago
Provectus net loss narrows 46.6% to $988,716 in Q2 FY26
  • Provectus Biopharmaceuticals posted a net loss of USD 988,716, narrowing 46.6% from a year earlier.
  • Operating loss narrowed 47.9% to USD 938,678 as total operating expenses fell 49.5% to USD 938,678.
  • Research and development expense dropped 85.1% to USD 131,130 on reduced clinical activity, including manufacturing and development work.
  • General and administrative costs declined 17.4% to USD 807,548, partly offset by higher insurance and software license renewals.
  • Cash rose to USD 1.16 million at June 30, 2026; working capital deficit was USD 6.34 million, with substantial doubt about going concern.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037671), on August 13, 2026, and is solely responsible for the information contained therein.